A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro

Oncology

Volumn 55, Issue SUPPL. 1, 1998, Pages 23-33

  Kurebayashi, Junichi ^a   Otsuki, Takemi ^a   Yamamoto, Shigeru ^a   Kurosumi, Masafumi ^b   Nakata, Taisuke ^c   Akinaga, Shir ^c   Sonoo, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antiestrogen; Breast cancer; Cell line; Fibroblast growth factor 1; Resistance

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; FULVESTRANT; KI 67 ANTIGEN; MESSENGER RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0032422986     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055256     Document Type: Conference Paper

References (40)

1. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM: Antiestrogens: Mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44:23-38.
2. Tonetti DA, Jordan VC: The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 1997; 62:119-128.
3. Nawata H, Bronzert D, Lippman ME: Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem 1981;256:5016-5021.
4. Nawata H, Chong MT, Bronzert D, Lippman ME: Estradiol-independent growth of a subline of MCF-7 human breast cancer cells in culture. J Biol Chem 1981;256:6895-6902.
5. Faye J-C, Jozan S, Redeuilh G, Baulieu E-E, Bayard F: Physicochemical and genetic evidence for specific antiestrogen binding sites. Proc Natl Acad Sci USA 1983;80:3158-3162.
6. Bronzert DA, Greene GL, Lippman ME: Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-1417.
7. Lykkesfeldt AE, Briand P: Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 1986; 53:29-35.
8. Watts CKW, Handel ML, King RJB, Sutherland RL: Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 1992;41:529-536.
9. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-3232.
10. Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 1994;59:121-134.
11. Gottardis MM, Jiang S-Y, Jeng M-H, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989;49: 4090-4093.
12. Wolf DM, Jordan VC: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 1994;31:117-127.
13. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991;83:1477-1482.
14. Dumont JA, Bitonti AJ, Wallance CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 1996;7:351-359.
15. Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure antiestrogens are sensitive to tamoxifen treatment. Int J Cancer 1995;61:529-534.
16. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
17. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SAW, Clarke R: MCF7/ LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-3493.
18. Mosselman S, Polman J, Dijkema R: ERβ: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53.
19. Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 1996; 82:2371-2374.
20. Katzenellenbogen BS, Korach KS: Editorial: A new actor in the estrogen receptor drama - Enter ER-β. Endocrinology 1997;138:861-862.
21. Kurebayashi J, Kurosumi M, Sonoo H: A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice. Br J Cancer 1995; 71:845-853.
22. Wakeling AE, Dukes M, Bowler J: A potent specific antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873.
23. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dosett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE: Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 1994;54:408-414.
24. Howell A, Defriend D, Robertson JFR, Blamey RW, Walton P: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30.
25. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 1993;53:2168-2177.
26. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IYF, Hanfelt J, McLeskey SW, Kern FG: MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997;15:2093-2108.
27. Kurebayashi J, Kurosumi M, Sonoo H: A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. Br J Cancer 1996;74: 200-207.
28. Klein-Hipass L, Schorpp M, Wagner U, Ryffel, GU: An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 1986;46:1053-1061.
29. Leygue E, Huang A, Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996;56:4324-4327.
30. McLeskey SW, Zhang L, Trock BJ, Kharbanda S, Liu Y, Gottardis MM, Lippman ME, Kern FG: Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br J Cancer 1996;73:1053-1062.
31. Singh Y, Shikata N, Kiyozuka Y, Nambu H, Morimoto J, Kurebayashi J, Hioki K, Tsubura A: Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo. Breast Cancer Res Treat 1997;45:15-27.
32. Zhang L, Kharbanda S, Hanfelt J, Kern FG: Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res 1998;58:352-361.
33. Halachimi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 1994;264: 1455-1458.
34. Cavailles V, Dauvois S, Danielian PS, Parker MG: Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 1994;91:10009-10013.
35. Smith CL, Onate SA, Tsai M-J, O'Malley BW: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996;93:8884-8888.
36. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerization in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
37. Wang TTY, Phang JM: Effects of estrogen on apoptosis pathways in human breast cancer cell line MCF-7. Cancer Res 1995;55:2487-2489.
38. Teixeira C, Reed JC, Christine Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 1995;55:3902-3907.
39. Kandouz M, Siromachkova M, Jacob D, Marquet BC, Therwath A, Gompel A: Antagonism between estradiol and progestin on BCL-2 expression in breast-cancer cells. Int J Cancer 1996;68:120-125.
40. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997;42:73-81.